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ABSTRACT
Objective Several genetic risk factors have been
identiﬁed for non-alcoholic chronic pancreatitis (NACP).
A genome-wide association study reported an
association of chronic pancreatitis (CP) with variants in
PRSS1–PRSS2 (rs10273639; near the gene encoding
cationic trypsinogen) and CLDN2–MORC4 loci
(rs7057398 in RIPPLY1 and rs12688220 in MORC4).
We aimed to reﬁne these ﬁndings in a large European
cohort.
Design We studied 3062 patients with alcohol-related
CP (ACP) or NACP and 5107 controls. Also, 1559
German patients with alcohol-associated cirrhosis or
alcohol dependence were included for comparison. We
performed several meta-analyses to examine genotype–
phenotype relationships.
Results Association with ACP was found for
rs10273639 (OR, 0.63; 95% CI 0.55 to 0.72). ACP was
also associated with variants rs7057398 and
rs12688220 in men (OR, 2.26; 95% CI 1.94 to 2.63
and OR, 2.66; 95% CI 2.21 to 3.21, respectively) and in
women (OR, 1.57; 95% CI 1.14 to 2.18 and OR 1.71;
95% CI 1.41 to 2.07, respectively). Similar results were
obtained when German patients with ACP were
compared with those with alcohol-associated cirrhosis or
alcohol dependence. In the overall population of patients
with NACP, association with rs10273639 was absent
(OR, 0.93; 95% CI 0.79 to 1.01), whereas rs7057398
of the X chromosomal single nucleotide polymorphisms
was associated with NACP in women only (OR, 1.32;
95% CI 1.15 to 1.51).
Conclusions The single-nucleotide polymorphisms
rs10273639 at the PRSS1–PRSS2 locus and rs7057398
and rs12688220 at the CLDN2–MORC4 locus are
associated with CP and strongly associate with ACP, but
only rs7057398 with NACP in female patients.
INTRODUCTION
The genetic susceptibility to chronic pancreatitis (CP)
is best illustrated by the discovery of cationic tryp-
sinogen mutations (PRSS1 HGNC:9475) in families
with autosomal-dominant inherited pancreatitis.1
There is also strong evidence that genetic variants
Signiﬁcance of this study
What is already known on this subject?
▸ Genetic associations for non-alcoholic chronic
pancreatitis (NACP) in PRSS1, PRSS2, CFTR,
SPINK1, CTRC and CPA1, as well as a
gene-dosage effect of PRSS1-PRSS2 locus have
been identiﬁed.
▸ Alcohol misuse is the predominant cause of
chronic pancreatitis (CP); however, only
3%–5% of alcohol misusers develop the
disease. This implicates genetic susceptibility
factors, which have not been elucidated so far.
▸ A recent genome-wide association study
(GWAS) reported PRSS1–PRSS2 and CLDN2–
MORC4 locus variants that affect risk for CP,
and the data have not been replicated up to
now.
What are the new ﬁndings?
▸ This study in a large European cohort replicates
and reﬁnes the impact of PRSS1-PRSS2 and
CLDN2-MORC4 locus variants as susceptibility
factors predominantly in ACP.
▸ Variants at both loci are susceptibility factors
for ACP and not alcohol misuse per se
according to our comparison with alcohol-
dependent and patients with alcoholic liver
cirrhosis.
▸ Risk increase for the X chromosomal
CLDN2-MORC4 locus is comparable in men and
women. As such this factor does not explain
any sex differences in disease susceptibility.
How might it impact on clinical practice in
the foreseeable future?
▸ The replication and reﬁnement of the recently
identiﬁed susceptibility variants justiﬁes further
studies on their functional properties.
▸ By the identiﬁcation of new pathways, new
strategies for inﬂuencing the clinical picture of
NACP and ACP might be developed in the long
term.
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contribute to cases of CP without a clear inheritance pattern.
Indeed, idiopathic CP (ICP) is associated with genetic alterations
in CFTR (HGNC:1884), SPINK1 (HGNC:11244), PRSS2
(HGNC:9483), CTRC (HGNC:2523) and CPA1
(HGNC:2296).2–7 The association of genetic variants and disease
susceptibility is less clear for alcohol-related CP (ACP). There is a
low enrichment of SPINK1 (p.N34S) and CTRC (p.R254W)
alleles in ACP populations, and no other consistent genetic risk
contributors have been described.5 8 Similar to ICP, the PRSS2
p.G191R variant protects against ACP development.2 All these
associations have been discovered through candidate-driven
genetic association studies.
A recent paper described a different approach and reported
novel risk and protecting loci for CP identiﬁed through a
genome-wide association study (GWAS). A number of variants
in the PRSS1–PRSS2 but also the CLDN2–MORC4 locus
(Claudin 2; HGNC:2041; RIPPLY1, ripply transcriptional
repressor 1, HGNC:25117; MORC4, MORC family CW-type
zinc ﬁnger 4, HGNC:23485) were captured as risk factors for
CP.9 This study investigated patients with different types of CP
as well as recurrent acute pancreatitis (RAP) and stratiﬁed indivi-
duals into alcohol-related and alcohol-unrelated pancreatitis
groups. In a ﬁrst screening cohort, three single nucleotide poly-
morphisms (SNPs) rs10273639 (in the PRSS1–PRSS2 locus on
chromosome 7, in perfect linkage disequilibrium with
rs2011216 in intron 1 and rs6667 in exon 5 of PRSS1),
rs7057398 and rs12688220 (both in a new locus, CLDN2–
MORC4 on the X chromosome) reached genome-wide signiﬁ-
cance. After scrutiny, the PRSS1–PRSS2 rs10273639 T allele
appeared to protect against CP, whereas RIPPLY1 rs7057398 C
allele and MORC4 rs12688220 T allele increased disease suscep-
tibility.9 There is some biological plausibility for the association
with the PRSS1–PRSS2 locus as it may disturb the balance of
pancreatic proteases and antiproteases in favour of the
former.10 11 Claudin 2 represents a tight junction protein
involved in low-resistance cation-selective ion and water trans-
port between endothelial cells.12 13 One might speculate that
CLDN2–MORC4 locus variants lead to miss-localisation of pan-
creatic CLDN2 that hampers its biological function. However,
this speculation warrants further experimental support.
Prior to the design of experimental studies that focus on the
biological role of these variants, it is crucial that GWAS results
are replicated. This is needed to prove that results are valid and
reliable to determine generalisability and to better judge the
effect size of the discovered association.14 We investigated the
association of PRSS1–PRSS2 and CLDN2–MORC4 locus var-
iants in a large European cohort of ACP and non-alcoholic CP
(NACP) to conﬁrm the former ﬁnding. In order to assess the
effect of alcohol consumption, we further reﬁned our analyses
by including cohorts of patients with alcohol-associated cirrhosis
(ALC) as well as with alcohol dependence (AD) without hepatic
or pancreatic disease.
MATERIALS AND METHODS
Study subjects
The respective medical ethical review committees of all partici-
pating centres approved the study protocol and all patients gave
written informed consent. The diagnosis of CP was based on
two or more of the following ﬁndings: (a) presence of a typical
history of recurrent pancreatitis or (b) recurrent abdominal pain
typical for CP, (c) calciﬁcations and/or (d) pancreatic ductal
irregularities revealed by imaging of the pancreas.15 ACP was
diagnosed in patients who had consumed at least 80 g ethanol
per day for at least 2 years in men or 60 g per day for women.
We labelled patients with NACP in the absence of exogenous
factors such as alcohol.
ALC was diagnosed by a history of habitual ethanol intake
(see ACP diagnosis above, duration at least 10 years), typical
ﬁndings in liver biopsy or clinical and laboratory ﬁndings indica-
tive for liver disease. Such laboratory and clinical ﬁndings
included abnormal levels of aminotransferases, gamma glutamyl
transpeptidase, coagulation tests, serum albumin concentration,
platelet count, complications related to liver cirrhosis such as
oesophageal varices, ascites, hepatic encephalopathy and typical
liver morphology in imaging studies. Other aetiologies of liver
cirrhosis were excluded by standard laboratory tests.
Patients with AD were recruited from psychiatric and addiction
medicine departments in different cities across southern and
central Germany. AD was diagnosed per DSM-IV criteria by con-
sensus of two clinical psychiatrists. All patients were of self-
reported German ancestry and did not suffer from CP or ALC.16
The study included 1866 patients (male, n=1567) with ACP
and 1196 patients (male, n=596) with NACP from different
European countries. In addition, we enrolled 5107 controls
(male, n=2287), 661 German patients with ALC (male, n=480)
and 898 Germans with AD (male, n=797). Characteristics of the
patients and controls are summarised in table 1. More details of
the controls are summarised in online supplementary table S1.
Genotyping
Details of the methods used for genotyping are summarised in
the online supplementary material. As quality controls, 3% of
all samples were genotyped in duplicates blinded to the investi-
gator. The concordance rate was >98%. Call rates for
rs10273639, rs7057398 and rs12688220 in the European
samples were 99.1% (9641/9730), 99% (9636/9730) and
98.8% (9609/9730), respectively.
Statistical analysis
Quality of SNP genotypes was assessed by study-wise call rate
and exact test for Hardy–Weinberg equilibrium in controls
(female controls only for the X chromosomal SNPs). We also
calculated overall statistics and performed stratiﬁed tests of
Hardy–Weinberg equilibrium according to Troendle and Yu.17
According to these measures, genotype qualities were excellent
throughout. Study-wise genetic effects were determined by
logistic regression analysis assuming an additive model of inher-
itance. For X chromosomal SNPs, we analysed the subgroups of
men and women separately. Following the approach of Loley
et al,18 we also determined combined effects by either assuming
a model of complete X inactivation (XIA) or no X inactivation
(nXIA) at all. The major purpose of our study is to compare
allele frequencies of risk variants between different subgroups of
patients (ACP, NACP) and controls (healthy, alcohol dependent,
patients with cirrhosis). Corresponding contrasts of interest are
listed in online supplementary table S2. Study-wise effects were
pooled by standard meta-analysis techniques as implemented
in the package ‘meta’ of the statistical software ‘R 3.0.1’
(ww.r-project.org). Heterogeneity between studies was assessed
using Q-statistics. Due to occasionally observed study heterogen-
eity, we calculated random-effect models throughout. For the
purpose of model diagnostics, we analysed and compared likeli-
hoods of XIA, nXIA and sex interaction. In ﬁgures 1, 2A, B, 3,
4A, B and 5, we present forest plots of our meta-analysis results
as well as other features. Finally, we performed a stratiﬁed ana-
lysis regarding age of onset in the German population. Forest
plots were generated using GraphPad Prism (V.6.0a) (San
Diego). p Values <0.05 were considered statistically signiﬁcant.
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Online supplementary ﬁgures S1a, b and S2a, b display the
results of X chromosomal analysis assuming models of complete
or no X inactivation.
RESULTS
PRSS1–PRSS2 locus (rs10273639)
In meta-analysis, rs10273639 showed the strongest association
with ACP (OR 0.63, 95% CI 0.55 to 0.72, p value 8.5×10−11).
No association was observed for NACP (OR 0.93, 95% CI 0.79
to 1.08, p value 0.3). An association was also observed for the
comparison between German patients with ACP and patients
with ALC (OR 0.58, 95% CI 0.50 to 0.66, p value 2.6×10−12).
The association was also found in comparison of German
patients with ACP with German patients with AD (OR 0.55,
95% CI 0.47 to 0.63, p value 2.3×10−16). Similar frequencies
of the SNP were observed in AD, ALC and healthy controls.
For patients with ACP coming from individual European
countries, an association was apparent for Germany, France,
the Netherlands, Hungary, Italy, Romania and the UK
(Germany OR 0.59, 95% CI 0.52 to 0.66, p value 2.9×10−19;
France OR 0.64, 95% CI 0.47 to 0.88, p value 0.007; the
Netherlands OR 0.56, 95% CI 0.43 to 0.72, p value
6.3×10−6; Hungary OR 0.43, 95% CI 0.18 to 0.94, p value
0.04; Italy OR 0.77, 95% CI 0.60 to 0.97, p value 0.03;
Romania OR 0.41, 95% CI 0.23 to 0.69, p value 0.001; the
UK OR 0.53, 95% CI 0.30 to 0.91, p value 0.02). The logistic
regression and meta-analysis results of rs10273639 are sum-
marised in ﬁgure 1, while the genotype frequencies for the
groups are given in online supplementary tables S3 and S4.
The TT genotype was underrepresented in all European
patients with ACP (all patients 9.5% vs all controls 18.1%, p
value 9.6×10−33, except for the samples from Poland (12.9%
patients vs 12.4% controls, p value 0.99)). In the NACP
cohorts, this underrepresentation was found only in German
patients (patients 13.8% vs controls 17.9%, p value 0.01).
RIPPLY1 (rs7057398)
In meta-analysis, signiﬁcant associations were found for
rs7057398 in male patients with ACP (OR 2.26, 95% CI 1.94
to 2.63, p value 5.4×10−26) and in female patients (OR 1.57,
95% CI 1.14 to 2.18, p value 0.007). Upon stratiﬁcation by
countries, we detected a signiﬁcant association with male
patients with ACP originating from Germany, France, Spain, the
Netherlands, Italy, Romania and the UK (p values 1.6×10−12,
0.0007, 0.03, 3.0×10−5, 3.1×10−5, 0.002 and 0.02, respect-
ively). We obtained similar results for female patients with ACP
from Germany, Poland and the UK (p value 0.004, 0.0005 and
0.04). We then assessed the strength of the association by com-
parison of the results obtained from patients with ALC and AD.
Indeed, rs7057398 was overrepresented in ACP relative to other
alcohol-related disorders. This was especially apparent for the
cohort of male German patients with ACP in comparison with
ALC (OR 2.32, 95% CI 1.80 to 3.01, p value 1.1×10−10) as
well as with AD (OR 2.03, 95% CI 1.64 to 2.51, p value
1.2×10−10). In addition, the SNP is not associated with risk of
cirrhosis or AD, neither for men nor for women. Figure 2A, B
summarises the results of the meta-analysis of rs7057398 in
patients with ACP. Results of XiA and nXiA are summarised in
online supplementary ﬁgure S1a, b.
The genotype and allele frequencies of rs7057398 in patients
with ACP are presented in online supplementary tables S5 and
S6. The C allele was more frequent in male patients with ACP
from all European countries investigated (43.8% vs controls
27.5%, p value 10×10−25) and the C allele was signiﬁcantly
overrepresented (p value 0.0001) in female patients with ACP
(35.2%) compared with controls (27.3%).
We detected a signiﬁcant association for rs7057398 with
NACP upon logistic regression in female patients (OR 1.30, 95%
CI 1.14 to 1.49, p value 1.3×10−4), but not in male patients
(ﬁgure 3). Estimated genetic effect sizes are always smaller than
for ACP. As shown in Supplementary tables S7 and S8, the C
allele was slightly overrepresented in male patients with NACP
(all patients: 32.6% vs 28.3%, p value 0.04; German patients:
Table 1 Characteristics of patients and controls
Country
ACP Controls
Number Male (%) Median age (years) Range (years) Number Male (%) Median age (years) Range (years)
Germany 871 747 (85.8) 50 20–86 2853 1232 (43.2) 56 18–81
France 90 76 (84.4) 51 30–73 1064 552 (51.9) n.a. n.a.
Spain 195 169 (86.7) 50 17–85 46 23 (50) 77 44–91
The Netherlands 237 181 (76.4) 56 33–80 441 166 (37.6) 50 18–99
Hungary 29 24 (82.8) 56 40–80 35 26 (74.3) 58 25–84
Italy 256 212 (82.8) 55 27–88 326 105 (32.2) 36 18–83
Romania 68 60 (88.2) 48 28–78 69 44 (63.8) 60.5 22–88
Poland 85 71 (83.5) 51 28–98 89 41 (46.1) 50 16–91
The UK 35 27 (77.1) 42 17–62 184 98 (53.3) 53 18–104
Country
NACP Controls
Number Male (%) Median age (years) Range (years) Number Male (%) Median age (years) Range (years)
Germany 694 338 (48.7) 16 0–71 2853* 1,232* (43.2) 56* 18–81*
France 415 210 (50.6) 16 1–20 1064* 552* (51.9) n.a.* n.a.*
The Netherlands 87 48 (55.2) 46 7–76 441* 166* (37.6) 50* 18–99*
Median age and range of age are displayed.
*Designates controls that were used for calculations to compare results with patients with alcohol-related CP (ACP) and NACP. In addition, 661 patients with alcohol-associated cirrhosis
(480 men; median age 53.5 years; age range 25–80 years) and 898 alcohol-dependent patients (797 men; median age 41 years; age range 18–80 years) from Germany were used for
comparison of results with German patients with ACP.
n.a., not available; NACP, non-alcoholic chronic pancreatitis; ACP, alcohol-related chronic pancreatitis.
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33.3% vs 27.1%, p value 0.03). Subgroup analyses revealed that
in German women and in the overall female patients with NACP
there was an overrepresentation of CC genotype (patients 10.1%
vs controls 7.8%, p value 2.6×10−4; patients 10.3% vs controls
8.6%, p value 4.2×10−5).
MORC4 (rs12688220)
Similar to the results obtained for rs7057398 in ACP,
rs12688220 was signiﬁcantly associated in male (OR 2.66, 95%
CI 2.21 to 3.21, p value 1.1×10−24) and female patients (OR
1.71, 95% CI 1.41 to 2.07, p value 3.3×10−8) with ACP
(ﬁgure 4A, B). The association was also statistically signiﬁcant in
individual male cohorts from Germany, France, Spain, the
Netherlands, Italy and Romania (p value 1.2×10−16, 8.4×10−6,
0.02, 2.5×10−6, 5.4×10−6 and 0.001, respectively), as well as
in the female cohorts from Germany, Poland and the UK
(p value 0.0003, 0.003 and 0.03). Results of XiA and nXiA are
summarised in online supplementary ﬁgure S2a, b.
Online supplementary tables S9 and S10 summarise the geno-
type and allele distribution of rs12688220 in ACP. The T allele
was overrepresented in all European male cohorts (men: all
patients 43.9% vs all controls 25.1%, p value 4.6×10−33),
while in female ACP cohorts from Germany, Poland and the UK
as well as in the overall female group the overrepresentation of
the TT genotype was statistically signiﬁcant (women: all patients
10.4% vs all controls 6.7%, p value 2.4×10−7).
In the meta-analysis, we detected no signiﬁcant association in
the overall male and female NACP group (p value 0.2 and 0.1).
Again, genetic effect sizes are clearly smaller than for ACP. In
single-study analyses, signiﬁcant differences were found in the
German NACP female group (OR 1.41, 95% CI 1.18 to 1.68, p
value 0.0002) and in the male NACP groups from Germany
(OR 1.34, 95% CI 1.03 to 1.75, p value 0.03) and the
Netherlands (OR 2.09, 95% CI 1.05 to 4.12, p value 0.03)
(ﬁgure 5).
Again, no differences were observed between the three
control groups. Genotype and allele distributions of this variant
can be found in online supplementary tables S11 and S12.
Additional analyses
We pooled our cases and control groups in order to compare
our results with the analysis published by Whitcomb et al.
Results are summarised in online supplementary table S13 for
all SNPs. Strong associations were observed for all variants, that
is, the results of Whitcomb et al are clearly replicated.
To analyse whether effect sizes of X chromosomal variants
are different between male and female patients, we performed
sex-interaction analysis but interaction terms were not signiﬁ-
cant throughout (results not shown). We also compared the
models of XIA and nXIA and observed a non-signiﬁcant trend
that XIA is more likely.
Finally, in order to better understand the lack of associations
for NACP, we performed a stratiﬁed analysis of the German
cohort regarding age of onset. Interestingly, we observed a trend
towards higher genetic effect sizes in groups of later age of
onset. This could explain, for example, the lack of associations
in the French cohort in which the age range is 1–20 years (see
online supplementary table S14).
DISCUSSION
This case–control study replicates and reﬁnes a robust associ-
ation between a PRSS1–PRSS2 locus variant (rs10273639) and
CP. This is particularly strong in ACP and not apparent in NACP.
The effect is independent from alcohol consumption as the
Figure 1 Meta-analysis results for rs10273639 (PRSS1–PRSS2) in patients with non-alcoholic chronic pancreatitis (NACP), alcohol-related chronic
pancreatitis (ACP) and comparison of German ACP patients with alcohol-associated cirrhosis (ALC) and with alcohol-dependent (AD) patients.
Results are presented in a semi-log scale.
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Figure 2 (A and B) Meta-analysis
results for rs7057398 (RIPPLY1) in
patients with alcohol-related chronic
pancreatitis (ACP) and comparison of
German ACP patients with alcohol-
associated cirrhosis (ALC) and with
alcohol-dependent (AD) patients.
Results are presented in a semi-log
scale.
Figure 3 Meta-analysis results for
rs7057398 (RIPPLY1) in patients with
non-alcoholic chronic pancreatitis
(NACP). Results are presented in a
semi-log scale. Y-axis intersects x-axis
at 1.
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Figure 4 (A and B) Meta-analysis
results for rs12688220 (MORC4) in
patients with alcohol-related chronic
pancreatitis (ACP) and comparison of
German ACP patients with
alcohol-associated cirrhosis (ALC) and
with alcohol-dependent (AD) patients.
Results are presented in a semi-log
scale.
Figure 5 Meta-analysis results for
rs12688220 (MORC4) in patients with
non-alcoholic chronic pancreatitis
(NACP). Results are presented in a
semi-log scale. Y-axis intersects x-axis
at 1.
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difference in allele frequency remained upon comparison with
other alcohol-related disorders (ALC and AD). The risk reduc-
tion by rs10273639 was higher in our overall ACP cohort (OR
0.63, CI 0.55 to 0.72) compared with the overall GWAS data
(OR 0.73, seOR 0.029), which might be explained by the
mixture of different aetiologies of patients with CP and RAP in
the recent publication.9 When using a comparable analysis strat-
egy, similar results were obtained (see online supplementary
table S13; OR 0.71, CI 0.61 to 0.84). Thus, the T allele confers
protection against the development of ACP, but not against
NACP. The protective effect of the T allele was observed for all
single studies except for the samples from Poland. Genetic effect
sizes vary between OR=0.41 (Romania) to OR=1.0 (Poland).
However, this can be explained by small sample sizes rather
than ethnic differences.
What is the biological background of our ﬁndings? The
PRSS1–PRSS2 locus SNP rs10273639 (c.−408T>C) is located
408 nucleotides upstream of the ATG start codon of PRSS1 and
as such might inﬂuence PRSS1 expression. Indeed, the SNP
seems to correlate with PRSS1 mRNA levels in 69 pancreas
tissue samples pointing towards its role in the regulation of
PRSS1 expression.9 Trypsinogen expression was lowest in TT
genotypes, which suggests that this genotype might protect
against pancreatitis development. However, the normalised gene
expression data from pancreatic tissue had high SEs and a
p value of 0.01 after removal of two outliers and, therefore,
probably warrant further evidence to support this assumption.9
In addition, SNPs rs2011216 and rs6667 were found to be in
linkage disequilibrium with rs10273639 and as such the bio-
logical effect might be related to those or even other SNPs.
We obtained similar results for the CLDN2–MORC4 locus
SNPs. We discovered that an association of both the RIPPLY1
and the MORC4 SNP with ACP was present in men and in
women. Genetic effect sizes in men were somewhat higher than
in women (OR=2.66 compared with OR=1.71 for MORC4
and OR=2.27 compared with OR=1.56 for RIPPLY1), but no
signiﬁcant SNP–sex interactions were found. The associations
with NACP were weaker throughout and not signiﬁcant except
for the RIPPLY1 variant in female patients.
In older epidemiological studies, it was shown that women
developed ACP at an earlier age and after consumption of a
lower total amount of alcohol than men.19 20 It is a matter of
debate whether genetic effects at chromosome X can explain
this observation. However, in our study, the genetic effect sizes
of men and women were not signiﬁcantly different for the var-
iants considered. Moreover, by comparing models with and
without assuming X inactivation, we did not receive a clear pref-
erence towards one of these assumptions. In view of these
results, the X chromosomal CLDN2-MORC4 locus variants do
not even partly explain the higher ACP risk in men.
The role of CLDN2/RIPPLY1/MORC4 in pancreatitis is less
clear. As a tight junction protein CLDN2 is involved in low-
resistance cation-selective ion and water transport between
endothelial cells.12 13 The functional consequence of each inves-
tigated SNP is rather unclear so far. The recent paper proposed
an atypical localisation of CLDN2 in acinar cells and an increase
of CLDN2 expression in one investigated CP pancreas specimen
(cDNA expression level) as well as in Western blot analyses
from 19 pancreas specimens with different genotypes. Both for
MORC4 and RIPPLY1 as well as for TBC1D8B, another gene
within the CLDN2 locus, the recent paper proposed no rele-
vance for CP development.
For the X chromosomal variants, the effect sizes were smaller
in a recently published GWAS.9 Again, this can be explained by
the markedly observed stronger genetic effect sizes of ACP com-
pared with NACP.
The aetiology of AD involves environmental and genetic
factors. Its heritability is estimated at ∼50%.21 Since patients
with ACP were compared with controls without deﬁned alcohol
consumption in our study as well as in the published GWAS, the
described SNPs might represent markers for alcoholism and not
for ACP. However, when data of patients with ACP were com-
pared with patients with alcohol-associated liver cirrhosis and
alcohol dependence in our study, the association of all investi-
gated SNPs was replicated with similar effect sizes. Therefore,
we conclude that the association of the three SNPs is speciﬁc for
ACP and is unrelated to AD or alcohol-related liver disease.
In summary, our data reﬁne the results of the recently pub-
lished GWAS. The PRSS1–PRSS2 rs10273639 T allele protects
against development of ACP but not NACP. The X chromo-
somal RIPPLY1 and MORC4 SNPs showed strong association
with ACP. For NACP, the associations are weaker and only sig-
niﬁcant for the RIPPLY1 SNP in women. The variants are not
associated with the risk of AD or liver cirrhosis. The observed
differences in SNP effects between ACP and NACP could be due
to interactions of variants with alcohol consumption, which
would amplify the risk, or they could result from differences in
the pathophysiology of the two forms of CP. These hypotheses
warrant future functional investigations.
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